{"blog": [], "keywords": [{"value": "Chronic Traumatic Encephalopathy", "name": "subject", "rank": "1", "is_major": "Y"}, {"value": "Football", "name": "subject", "rank": "2", "is_major": "Y"}, {"value": "Food and Drug Administration", "name": "organizations", "rank": "3", "is_major": "Y"}, {"value": "Brain", "name": "subject", "rank": "4", "is_major": "Y"}, {"value": "Sports Injuries", "name": "subject", "rank": "5", "is_major": "Y"}, {"value": "National Football League", "name": "organizations", "rank": "6", "is_major": "N"}, {"value": "University of California, Los Angeles", "name": "organizations", "rank": "7", "is_major": "N"}], "web_url": "http://www.nytimes.com/2015/04/12/sports/football/fda-warns-researchers-on-claims-and-marketing-of-drug-to-detect-brain-disease.html", "document_type": "article", "byline": {"person": [{"lastname": "BELSON", "firstname": "Ken", "role": "reported", "organization": "", "rank": 1}], "original": "By KEN BELSON", "contributor": ""}, "type_of_material": "News", "multimedia": [], "section_name": "Sports", "word_count": "554", "source": "The New York Times", "subsection_name": "Pro Football", "lead_paragraph": "Researchers at U.C.L.A. have been developing a biomarker that aims to identify tau protein deposits in the brain, a signature of C.T.E., when patients are given a PET scan.", "pub_date": "2015-04-12T00:00:00Z", "news_desk": "Sports", "headline": {"print_headline": "Researchers Seeking to Find a Brain Disease in Living Patients Are Under F.D.A. Scrutiny", "main": "F.D.A. Warns Researchers on Claims of Drug to Detect Brain Disease"}, "print_page": "4", "snippet": "Researchers at U.C.L.A. have been developing a biomarker that aims to identify tau protein deposits in the brain, a signature of C.T.E., when patients are given a PET scan.", "_id": "552980b638f0d81a55c4e953", "slideshow_credits": null, "abstract": "Researchers at UCLA who developed drug aimed at diagnosing chronic traumatic encephalopathy, degenerative brain disease linked to repeated head trauma, have come under fire by Food and Drug Administration for improperly marketing drug and making overstated claims about its efficacy."}